172 related articles for article (PubMed ID: 10864338)
21. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
22. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
23. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
Hurry M; Eccleston A; Dyer M; Hoskins P
Int J Technol Assess Health Care; 2020 Apr; 36(2):104-112. PubMed ID: 32423520
[TBL] [Abstract][Full Text] [Related]
24. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.
Wainberg S; Husted J
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):1989-95. PubMed ID: 15598752
[TBL] [Abstract][Full Text] [Related]
25. Changes in specialists' perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination: then and now.
Matloff ET; Bonadies DC; Moyer A; Brierley KL
J Genet Couns; 2014 Apr; 23(2):164-71. PubMed ID: 23852268
[TBL] [Abstract][Full Text] [Related]
26. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
[TBL] [Abstract][Full Text] [Related]
27. Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
Ann Intern Med; 2006 Mar; 144(6):I40. PubMed ID: 16549849
[No Abstract] [Full Text] [Related]
28. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
Norum J; Hagen AI; Maehle L; Apold J; Burn J; Møller P
Eur J Cancer; 2008 May; 44(7):963-71. PubMed ID: 18362067
[TBL] [Abstract][Full Text] [Related]
30. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
31. [INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer].
Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
Ann Endocrinol (Paris); 1998; 59(6):470-84. PubMed ID: 10189990
[TBL] [Abstract][Full Text] [Related]
32. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic surgery for women at high risk for breast cancer.
Blanchard DK; Hartmann LC
Clin Breast Cancer; 2000 Jul; 1(2):127-34; discussion 135. PubMed ID: 11899651
[TBL] [Abstract][Full Text] [Related]
35. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
Agnantis NJ; Paraskevaidis E; Roukos D
Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
[No Abstract] [Full Text] [Related]
36. Risk of breast cancer in carriers of BRCA gene mutations.
Birkmeyer JD; Welch HG
N Engl J Med; 1997 Sep; 337(11):787-8; author reply 789. PubMed ID: 9289638
[No Abstract] [Full Text] [Related]
37. Risk of breast cancer in carriers of BRCA gene mutations.
Orlando R
N Engl J Med; 1997 Sep; 337(11):787; author reply 789. PubMed ID: 9289637
[No Abstract] [Full Text] [Related]
38. Cost-effectiveness of testing for breast cancer susceptibility genes.
Holland ML; Huston A; Noyes K
Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
Metcalfe KA; Liede A; Hoodfar E; Scott A; Foulkes WD; Narod SA
J Med Genet; 2000 Nov; 37(11):866-74. PubMed ID: 11073541
[TBL] [Abstract][Full Text] [Related]
40. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Kim-Sing C; Ghadirian P; Sun P; Narod SA
Clin Genet; 2014 Jan; 85(1):21-30. PubMed ID: 23859469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
